semaglutide recombinant synthesis Method for preparing by biochemical method - Eureka Semaglutide Manufacturing Process - Consensus

semaglutide main chain P29

For SPPS, every addition of an amino acid requires repeated washing steps, generating large volumes of hazardous solvent waste

The line between peptide and protein is blurry: while the FDA uses a conservative cut off of 40 a.a., this would exclude insulin (~51 a.a.)

Two carboxyl groups on a side chain disclosed by patent CN111378028A are naked and are not protected by a protective group, the purity of an intermediate obtained in the subsequent coupling reaction with an Arg34GLP-1 (9-37) main peptide chain is not high, only 67.5 percent is obtained, the yield is seriously reduced, and the pH value in the reaction has a large influence on the side chain modification, so that various byproducts which are difficult to remove are easily generated, such as a double-modified impurity byproduct with both the 26 th position and the end position of the main peptide chain modified and a byproduct with the end position of the main peptide chain modified

Thoroughly review all warnings and essential safety information regarding these drugs.See important safety information